Company intelligence / Profile preview
Suncadia Pharmaceuticals
Beijing, Beijing, Chinahengrui.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suncadia Pharmaceuticals (Beijing, Fujian, Chengdu) operate as subsidiaries of Jiangsu Hengrui Medicine, focusing on new chemical, peptide, and antibody drugs for cardiovascular, endocrine, metabolic, infectious, and nervous system diseases and have multiple late-stage clinical candidates[1][3][7].
- Therapeutic areas
- OncologyPulmonologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeAntibodySynthetic peptidesiRNAChemical drugs
- Industry
- Pharma
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Suncadia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suncadia Pharmaceuticals.